

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)



(10) International Publication Number
WO 2021/152119 A1

(51) International Patent Classification:

A61K 38/21 (2006.01) *A61M 15/00* (2006.01)
A61K 38/22 (2006.01) *A61P 11/00* (2006.01)
A61M 11/00 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/052151

(22) International Filing Date:

29 January 2021 (29.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20000053.7 31 January 2020 (31.01.2020) EP
20000121.2 20 March 2020 (20.03.2020) EP

(71) Applicant: **ADVITA LIFESCIENCE GMBH** [DE/DE];
Alte Bundesstraße 20, 79194 Gundelfingen (DE).

(72) Inventors: **KLAPPROTH, Holger**; Kehler Str. 12,
79108 Freiburg (DE). **BEVEC, Dorian**; Frankfurter Str.
11, 61231 Bad Nauheim (DE). **FRYE, Björn Chris-
tian**; Sebastian-Kneipp-Str. 15a, 79104 Freiburg (DE).
MÜLLER-QUERNHEIM, Joachim; Am Kohlbach 2,
79199 Kirchzarten (DE). **VON WEGENER, Jörg**; Ruh-
lebener Strasse 20, 13597 Berlin (DE). **HOPPE, Wolf-
gang**; Zum Roten Stein 8, 79108 Freiburg-Hochdorf (DE).
KESSEMEIER, Marc A.; An der Rothhalde 9/1, 79312
Emmendingen (DE).

(74) Agent: **MERTZLUFFT-PAUFLER, Cornelius** et al.;
Urachstraße 23, 79102 Freiburg (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: HUMAN ANTI-INFLAMMATORY PEPTIDES FOR THE INHALATORY TREATMENT OF INFLAMMATORY PUL-
MONARY DISEASES

(57) Abstract: The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.



WO 2021/152119 A1